AGMB

AgomAb Therapeutics NV

Nasdaq · Biological Products, (No Diagnostic Substances)

Insider trades

Congress trades

Company Overview

A concise company profile alongside the latest public filing activity.

AgomAb Therapeutics is a biotechnology company developing therapies that target the hepatocyte growth factor/MET pathway to promote tissue regeneration, with programs focused on lung and liver disease.

Industry

Biological Products, (No Diagnostic Substances)

Headquarters

Antwerpen

Exchange

Nasdaq

Company profile sourced from SEC filings.

Corporate Insider Trades

Open-market purchases and sales by directors, officers, and other company insiders.

Insider	Type	Value	Shares / Price	Date
Epstein David RDirector	Buy	$45K	5,000at $8.90	Oct 8, 2026
Epstein David RDirector	Buy	$44K	5,000at $8.70	Oct 6, 2026
Kemula Pierre Thadee VictorChief Financial Officer	Buy	$26K	3,000at $8.67	Oct 6, 2026
Kemula Pierre Thadee VictorChief Financial Officer	Buy	$43K	5,000at $8.57	Oct 6, 2026
Epstein David RDirector	Buy	$43K	5,000at $8.57	Oct 5, 2026
Knotnerus Tim JasperChief Executive Officer	Buy	$51K	6,000at $8.48	Oct 5, 2026
Knotnerus Tim JasperChief Executive Officer	Buy	$44K	5,000at $8.70	Oct 6, 2026
Kemula Pierre Thadee VictorChief Financial Officer	Buy	$17K	2,000at $8.54	Oct 6, 2026

Source: SEC EDGAR Form 4 filings

Congressional Trades

Recent disclosures by members of the U.S. House and Senate.

No recent congressional disclosures found for AGMB.

Source: Senate eFD and House Clerk STOCK Act disclosures

Get notable AGMB activity by email

Free alerts for the insider and congressional trades worth watching.

Email address

Mobile number (optional)

SMS is optional: we only save your number if you check the consent box and provide a valid number. Outside US/Canada, include + and your country code.

By checking this box and submitting, I agree to receive recurring automated marketing text messages from MySmarTrend (Ramy LLC) at the mobile number provided, including market alerts, commentary, and offers for MySmarTrend products and subscriptions. Messages may begin when the SMS program launches. Message frequency varies. Message and data rates may apply. Consent is not a condition of purchase or email signup. Reply STOP to opt out or HELP for help once messaging begins. Before launch or at any time, contact privacy@mysmartrend.com to withdraw consent or get help. I agree to the SMS Terms and acknowledge the Privacy Policy.

SMS Terms and Privacy Policy.

By submitting your email address, you will receive a free subscription to the MySmarTrend e-letter, and offers from us and our affiliates that we think might interest you. You can unsubscribe at any time. Privacy Policy.

For informational purposes only, not investment advice. Filings can be delayed, corrected, or amended. Trading activity alone does not predict future performance.